
Opinion|Videos|July 24, 2024
Long-Term Follow-Up from CheckMate 9LA at ASCO 2024
Author(s)Jason Porter, MD
A key opinion leader examines the overall survival data from the CheckMate 9LA study, which evaluated nivolumab plus ipilimumab plus chemotherapy in metastatic non-small cell lung cancer patients, and explores how the long-term follow-up results inform treatment decisions in this setting.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Discuss the data that was presented at the ASCO 2024 on overall survival from the
CheckMate 9LA study with the use of nivolumab + ipilimumab + chemotherapy in patients with metastatic NSCLC. - What are your key takeaways from this study?
- How do you think the long term follow up data supports decision-making in metastatic NSCLC?
Advertisement
Related to this article

Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.

The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.

A historical review traces Sjögren disease from its early descriptions to the use of salivary gland ultrasound in diagnosis.

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.

Postpartum navigation missed its primary goal but raised postpartum visits and primary care use among Medicaid-insured patients.

Stigma, years-long diagnostic delays, and limited follow-up after a crisis remain hurdles for people with serious mental illness, experts say.

MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.
Advertisement
Advertisement
Trending on AJMC
1
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
2
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
3
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
4
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
5

